TNFSF13B and myasthenia gravis: <h4>Objective</h4>This real-world study evaluated the efficacy and safety of telitacicept, a dual BAFF/APRIL inhibitor, in patients with generalized myasthenia gravis (MG).<h4>Methods</h4>In this retrospective study, 17 myasthenia gravis patients on stable background therapy received weekly subcutaneous telitacicept (160-240 mg).